Document Detail

The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans.
MedLine Citation:
PMID:  2371944     Owner:  NLM     Status:  MEDLINE    
Earlier specific cell-mediated immune reactions and their modulation by different drugs were reported against human vascular antigens in patients with vascular diseases. Presently the effect of Etofibrate (Lipo-Merz) was studied on cellular immune reactions induced by human aorta with lipid plaques and on serum lipid parameters in 46 men with acute myocardial infarction and in 48 men with arteriosclerosis obliterans compared to 40 healthy controls. Leucocyte migration test and lymphocyte-mediated cytotoxicity were repeatedly investigated in the presence of human aortic extract with or without Etofibrate (2 micrograms/50 microliters). The degree of leucocyte migration inhibition and of lymphocyte-mediated cytotoxicity proved to be similar in hypherlipaemic and in normolipaemic groups. Etofibrate could decrease cellular immune reactions both in hyperlipaemic and normolipaemic patients, but its effect was more expressive in the hyperlipaemic than normolipaemic group. Three months later a reduction of cellular immune reactions was found mainly in normolipaemic patients. Ten patients with myocardial infarction and 10 arteriosclerosis obliterans patients were treated with Etofibrate (900 mg/day) for 12 weeks. After therapy, cholesterol, triglycerides, LDL concentrations were reduced, HDL level was increased and the rate of LDL:HDL decreased. Leucocyte migration inhibition and lymphocyte-mediated cytotoxicity were also diminished. This time the cellular immune reactions of treated patients were only slightly reduced "in vitro" by Etofibrate in contrast with non treated hyper- and normolipaemic patients in whom cellular immune reactions were decreased by Etofibrate similarly to the first determinations. On the basis of our observations Etofibrate may be useful in the therapy of arteriosclerotic vascular diseases with or without hyperlipaemia, because it could decrease the cellular sensitization against aortic tissue.
M Horváth; M Varsányl; N Jovanovich; L Romics; S Gerö
Related Documents :
6733284 - Erythroid progenitors in adult chronic pure red cell aplasia: relationship of in vitro ...
11594854 - Identification of clonal t cells in the blood of patients with systemic sclerosis: posi...
7995374 - A pathogenetic link between aplastic anemia and paroxysmal nocturnal hemoglobinuria is ...
7788514 - Soluble serum interleukin 2 receptors in patients with asthma and allergic bronchopulmo...
16424784 - Losartan and prevention of atrial fibrillation recurrence in hypertensive patients.
401664 - Thyrotoxicosis: relations between clinical state and biochemical changes during carbima...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Allergologia et immunopathologia     Volume:  18     ISSN:  0301-0546     ISO Abbreviation:  Allergol Immunopathol (Madr)     Publication Date:    1990 Mar-Apr
Date Detail:
Created Date:  1990-08-17     Completed Date:  1990-08-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370073     Medline TA:  Allergol Immunopathol (Madr)     Country:  SPAIN    
Other Details:
Languages:  eng     Pagination:  95-9     Citation Subset:  IM    
3rd Department of Medicine, Semmelweis Medical University, Budapest, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antilipemic Agents / pharmacology*,  therapeutic use
Aorta / immunology
Arteriosclerosis Obliterans / blood,  immunology*
Cell Migration Inhibition
Clofibrate / analogs & derivatives*
Clofibric Acid / analogs & derivatives*,  pharmacology,  therapeutic use
Cytotoxicity Tests, Immunologic
Hyperlipidemias / blood,  drug therapy,  immunology*
Immunity, Cellular / drug effects*
Lipids / blood*
Middle Aged
Myocardial Infarction / blood,  immunology*
T-Lymphocytes / drug effects,  immunology
Reg. No./Substance:
0/Antilipemic Agents; 0/Lipids; 31637-97-5/etofibrate; 637-07-0/Clofibrate; 882-09-7/Clofibric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Lymphocyte response to IgE regulatory factors in allergic patients during the course of immunotherap...
Next Document:  Time of onset of symptoms of acute myocardial infarction.